GLP-1 receptor agonists have become an integral part of diabetes management, especially for type 2 diabetes, due to their ability to regulate blood sugar levels, promote weight loss, and improve overall glycemic control
Autor previously served as deputy commissioner for global regulatory operations and policy at the FDA and held a senior position at AstraZeneca
Participants with obesity who received the 12mg dose lost an average of 28.7% of their body weight at 68 weeks, translating to an average of 71.2 pounds from a baseline weight of approximately 248 pounds
Other injectable weight loss medications may also cause dizziness
The appropriate injection site depends on the prescribed medication, body composition, syringe, and individualized instructions provided by your healthcare provider
Most side effects peak during dose escalation and improve at maintenance dose